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One Sentence Summary: Specific, covalent, mechanism-based inhibitors of influenza 
neuraminidase function as potent (IC50 = 1 – 10 nM) antiviral agents in vitro and protect mice 
against infection. 
 
 
 Abstract: Influenza antiviral agents play important roles in modulating disease severity and in 
controlling pandemics while vaccines are prepared, but the development of resistance to agents 
like the commonly used neuraminidase inhibitor Tamiflu may limit their future utility. We report 
here a completely new class of specific, mechanism-based anti-influenza drugs that function via 
the formation of a highly stabilized covalent intermediate in the neuraminidase enzyme, and 
confirm this mode of action via structural and mechanistic studies. These compounds function 
not only in cell-based assays, but also in animal models, with efficacies comparable to that of 
Relenza and with broad spectrum activity against drug-resistant strains in vitro. With their great 
structural similarity to the natural substrate, and their novel mode of action based upon the 
enzyme mechanism, this class of drug should be less prone to resistance development, offering a 
new approach to the control of influenza. 
 
Main Text:  
The envelope of the influenza virus contains two immunodominant glycoproteins, 
hemagglutinin (HA) and neuraminidase (NA), that play key roles in viral infection and spread. 
HA effects attachment of the virus to the host cell via its interaction with surface sialic acids, 
thereby initiating entry. Once the virus has replicated, the NA cleaves sialic acids from the viral 
and cell surfaces, allowing the virus progeny to spread to uninfected cells. The specific antigenic 
properties of the different HAs and NAs are used to classify influenza type A viruses into 
subtypes (H1-17 and N1-9). These in turn can be categorized into two groups on the basis of 
neuraminidase phylogeny: Group 1 contains N1, N4, N5 and N8, while Group 2 contains N2, 
N3, N6, N7 and N9. Based on the notion that potent and specific viral NA inhibitors should 
function to reduce viral spread, structure-based inhibitor design programs have produced two 
widely used anti-influenza drugs, zanamivir (Relenza®) and oseltamivir (Tamiflu®) (Fig. 1A). 
Oseltamivir figured prominently in the control of the recent H1N1 pandemic. The initial design 
of these drugs was based upon the mimicry of the flattened transition state conformation of the 
sugar through incorporation of an endocyclic alkene within a carbocycle (oseltamivir) or a 
pyranose ring (zanamivir) (1). Specificity for the influenza enzyme over other neuraminidases, 
along with additional affinity, was provided by incorporation of a guanidinium or ammonium 
substituent at the position corresponding to C-4 of the natural substrate to interact with a highly 
conserved anionic pocket at that location in the active site. These broad spectrum influenza drugs 
are active against NAs from group 1 and 2 influenza A strains as well as influenza B.   
We are now seeing the emergence of drug-resistant strains, particularly against the more 
widely used and structurally divergent drug oseltamivir. Mutations can be both drug- and 
influenza subtype- specific. The most commonly seen mutation in viruses with the N1 subtype is 
H275Y which interferes with binding of the isopentyl side chain of oseltamivir, but still permits 
binding of zanamivir and the natural substrate. Mutations most commonly detected in clinical 
isolates with the N2 subtype include R292K (2-4) and E119V (3, 4). Like the H275Y, the R292K 
precludes full rotation of the E276 necessary to create the hydrophobic pocket that 
accommodates the pentyl side-chain of oseltamivir (5). In contrast, E119V confers oseltamivir 
specific resistance due to altered interactions with the 4-amino group. E119A,D,G mutations 
seen in vitro (6, 7) affect binding of oseltamivir and/or zanamivir, demonstrating the critical 
nature of the interactions of C-4 amino or guanidino group for high affinity binding. Some of the 
recent mutations seen in pandemic H1N1 viruses, including I223R, confer reduced sensitivity to 
both inhibitors (8-10). The emergence of these mutant strains highlights an urgent need for new 
classes of NA inhibitors that differ minimally in structure from the parent sialic acid, given that 
the development of resistance to structurally conservative, mechanism-based inhibitors should be 
a much less probable event (5).  
 
Difluorosialic acids are covalent NA inhibitors that react with Y406 as the catalytic 
nucleophile 
NAs catalyze the hydrolysis of sialosides by a process resulting in net retention of 
stereochemistry at the site of substitution. A mechanism involving an ion-pair intermediate has 
long been suggested for the GH34 (11) influenza NA (12), though involvement of a covalent 
intermediate, as has been shown for GH33 NAs (13), has emerged as an alternative. We here 
provide the first evidence for a covalent intermediate formed in the course of the reaction 
catalyzed by the influenza NA by use of 2,3-difluorosialic acid (1, DFSA) (Fig. 1B) as a 
substrate that exhibits slow turnover. The electronegative fluorine atom at C-3 inductively 
destabilizes the oxocarbenium ion-like transition states for both formation and hydrolysis of the 
intermediate, thus slowing each step, while the C-2 anomeric fluoride leaving group speeds the 
formation step, permitting accumulation of the covalent intermediate (Fig. 1B). Rapid 
inactivation of NA was observed at low inactivator concentrations, such that individual kinetic 
parameters (Ki and ki) could not be determined for the N9 NA; only a second order rate constant 
ki /Ki of 196 min
-1
mM
-1
 could be measured. Turnover of the covalent intermediate (khydr) also 
occurred rapidly, with a t1/2 < 1 minute. Confirmation of the formation of a covalent species and 
identification of the site of attachment was achieved by peptic digestion of N9 NA that had been 
labeled with 2,3-difluorosialic acid 1, or by its difluoroKDN analogue as shown in fig. S1-3. 
Isolation and subsequent sequence analysis of the labeled peptide by LC/MS-MS identified this 
peptide as NTDWSGYSSSGSF, with the tyrosine (Y) bearing the sugar label. This provides 
direct evidence for a role of Y406 as the catalytic nucleophile.   
 
With the knowledge that that the influenza NAs employ a covalent mechanism, we embarked on 
a program to explore these 2,3-difluoro sialic acids (DFSAs) as a possible new class of 
mechanism-based influenza therapeutics that inhibit by covalently blocking the active site. This 
is an attractive approach since not only can the initial affinity of the drug (Ki) be optimized, but 
also, the relative rate constants for formation (ki) and hydrolysis (khydr) of the trapped 
intermediate, with the objective being to optimize the ratio of ki/khydr. Such a strategy has worked 
well previously for the β-lactam antibiotics, and may provide particularly favorable 
pharmacokinetic behavior in this situation. Indeed covalent drugs are regaining respect, with 
three of the top-selling drugs in the U.S. being covalent inhibitors of their targets (14). Key 
improvements required to convert 1 into a useful drug candidate are therefore to introduce 
selectivity for the viral NA over host enzymes and to drastically reduce rates of turnover (khydr). 
Since the incorporation of an equatorial cationic nitrogen substituent at the site equivalent to OH-
4 of sialic acid provided a substantial affinity boost within zanamivir and oseltamivir, it was of 
interest to synthesize versions of 1 bearing amine (Am) and guanidine (Gu) substituents at C-4. 
Not only might these electron-withdrawing substituents improve the initial affinity and the 
specificity for the influenza enzyme, but also turnover of the intermediate may be further slowed, 
due both to the additional stabilization of the bound intermediate provided through improved 
interactions with the enzyme, and to the added inductive effect of the substituent on the reaction 
transition state. The effects of axial (ax) or equatorial (eq) stereochemistry of F3 on inhibitory 
behavior were also explored. 
 Synthesis of the protected diastereomeric 3-axial and 3-equatorial-2,3-difluoro-4-azido 
neuraminic acids as key intermediates was achieved by Selectfluor™ hydroxyfluorination of 2,4-
dideoxy-2,3-didehydro-4-azido-N-acetylneuraminic acid (4-azido-DANA) (15) followed by 
installation of an equatorial fluorine at C-2 using diethylaminosulfur trifluoride (DAST). The 
lead candidates shown in Table 1, FaxAmDFSA (2), FaxGuDFSA (3), FeqAmDFSA (4) and 
FeqGuDFSA (5) were then prepared by reduction or reductive guanidylation, followed by 
deprotection. Full synthetic details and product characterization are provided as Supplementary 
Materials. 
 
Selective inhibition of influenza virus NA in vitro 
Kinetic parameters for inactivation and reactivation of N1, N2 and N9 NAs, as 
representatives of the Group 1 and Group 2 enzymes, by 2 - 5 are presented in Tables 1 and S4, 
along with parameters for the parent 2,3-difluorosialic acid 1 with the N9 NA. As noted, 
inactivation by 1 was too fast, even at 4 
o
C, for individual parameters of the inactivation rate (ki) 
and binding (Ki) constants to be measured, thus only the second order rate constant (ki/Ki) was 
determined. Rate constants for turnover by hydrolysis (khydr) were determined by monitoring the 
time course of reactivation of dialyzed, inactivated enzyme, and fitting the data to a first order 
expression. First order rate constants for inactivation and reactivation are also expressed in the 
form of half-lives for each process in Table 1. 
Gratifyingly, not only does incorporation of the charged substituent at C-4 result in high 
initial affinity, but also, more importantly, it greatly reduces the rate constant for reactivation of 
enzymes inactivated by 2, 3, 4  and 5. Half-lives for reactivation of NAs labeled by 2, 3, 4 and 5 
ranged from 0.75 h to >100 h. These very slow turnover rates are extremely important as they 
mean that the virus will remain inactivated for extended times, even after the compound may 
have been cleared from relevant tissues, with favorable consequences for pharmacokinetic 
behavior. Interestingly, compounds with an equatorial fluorine at C-3 inactivate and reactivate 
faster than do those with an axial fluorine, typically by 10-40 fold. Further, the presence of a 
guanidine substituent at C-4 slows both the inactivation and reactivation more than does an 
amine substituent, with a much greater effect on the reactivation step. Since the two transition 
states (for formation and hydrolysis) will be very similar, this difference in rate likely has its 
origins in optimized interactions of the guanidine with the active site at the stage of the covalent 
intermediate, as is seen in the crystal structure of the trapped species shown in Fig. 1C. A 
covalent bond of 1.45 Å is clearly observed in the electron density map (Fig. 1C, table S1), 
between C-2 of 3-fluoro (eq) sialic acid and the phenolic oxygen of Y406. As observed 
previously in a structure of the GH33 sialidase NanI (16), the covalent intermediate species is 
accompanied by an unsaturated form of fluorosialic acid formed by elimination. The carboxylate 
groups of both bound species form electrostatic interactions with the guanidine groups of the 
strictly conserved arginine triad R118, R292 and R371, a key interaction common among 
existing NA inhibitors. However, the elimination product forms stronger interactions (≤3 Å) with 
R118 and R371 (fig. S4) similar to those formed with zanamivir, while the covalent intermediate 
exhibits shorter contacts (≤3 Å) with R292 (Fig. 1D). In addition to many other interactions that 
have been observed in previous complexes of N9 NA with zanamivir (17), both forms of 
FeqGuDFSA also form electrostatic interactions at 2.9-3.4 Å (Fig. 1D and fig. S4) between the 
equatorial fluorine and the positive charge of the guanidine group of R118, reminiscent of those 
seen in other protein/ligand systems (18), possibly explaining the higher initial affinity of the 
FeqGuDFSA (5) inhibitor compared to others. The C-4 guanidine indeed forms strong 
interactions with the anionic pocket, very similar to those found with zanamivir (1), thereby 
contributing to stabilization of the intermediate. 
An absolute comparison of the in vitro efficacy of these compounds as enzyme inhibitors 
with those of zanamivir or oseltamivir is difficult and not necessarily instructive given their 
different modes of action, covalent versus non-covalent and the time-dependence of inhibition: 
quite different results are obtained at different assay intervals (19). However, a pragmatic 
measure was achieved by measuring IC50 values for each DFSA, as well as zanamivir and 
oseltamivir carboxylate (oseltamivir from which the pro-drug ester had been hydrolyzed), against 
four different virus strains after pre-incubation for 30 minutes prior to substrate addition. The 
IC50 values so obtained are presented in Table 2, along with data for mutant viruses to be 
discussed below. Comparison between pairs of DFSAs again confirms that, in almost all cases, 
each compound with an equatorial fluorine is a superior inhibitor to its epimer with an axial 
fluorine, indicating that, under these conditions, improved rates of inactivation are important.  
Likewise, in each case the guanidine derivative showed superior performance to its amine 
analogue. Consequently, compound 5 (FeqGuDFSA) was the optimal derivative within the 
series. Comparison of these IC50 values with those for zanamivir and oseltamivir reveals that, on 
this measure, the compounds with an equatorial fluorine are of comparable efficacy, particularly 
when the guanidine is present. Further, their “on-rates” are superior to those of zanamivir, while 
off-rates are enormously slower (1, 20, 21). 
The specificity of these inhibitors was then evaluated by testing them against Neu2 as a 
representative human NA (all human NAs belong to the sequence-related family GH33). No 
inactivation of Neu2 was seen with either of the amine derivatives, and inactivation by 
FaxGuDFSA (3) and FeqGuDFSA (5) occurred slowly, but at rates some 10
5
 – 106 lower than 
seen for inactivation of NA at comparable concentrations. This behavior is a considerable 
improvement over zanamivir, which inhibits Neu2 with a Ki of 17 M, only 10
3
 – 104 fold 
higher than for NA (22).  
 
Effects on influenza virus replication 
Based upon these very promising results the ability of compounds 2 - 5 to inhibit the replication 
of the virus in cell culture was explored using MDCK cells. Three A strains (N1, N2 and N9) 
plus one B strain were tested in plaque size reduction assays (PRA), with zanamivir used as a 
control. While absolute sensitivity in the PRA depends on both the affinity of the HA for cell 
receptors as well as the NA function (23, 24), it is a useful assay for determining relative 
sensitivity to inhibitors. The PRA data showed that all DFSAs inhibited virus replication (Table 
3, figs. S5-S8) with no cytotoxicity observed even at 5 mM DFSA concentrations, as measured 
by neutral red staining of viable cells. The H3N2 virus was less susceptible to all inhibitors 
compared to the other strains (fig. S7), due to the lower affinity of its HA, which allows viral 
spread with less NA activity (25). However, for all strains, substitution with the 4-amino group 
enhanced inhibition over the parent DFSA, and the 4-guanidino substitution further enhanced 
inhibition of virus replication. It is interesting that the stereochemistry of the fluorine substituent 
had little effect on efficacy for the compounds with a 4-amino substituent, apart from possibly a 
small enhancement with the B virus. However the presence of an equatorial fluorine in the 4-
guanidino version resulted in a further 10-fold enhancement in potency for three strains tested, 
the one exception being G70C (H1N9), which was particularly well inhibited by the axial 
version also (fig. S8). Consequently, FeqGuDFSA (5) had the highest potency of all of the 
inhibitors, including zanamivir, against the influenza B virus (fig. S5) and performed comparably 
against the influenza A strains. Two points are particularly noteworthy at this stage. One is that 
this behavior in PRA largely mirrors the in vitro kinetic data, with the compounds possessing an 
equatorial fluorine being superior to those with an axial fluorine, and the 4-guanidino 
substitution being superior to a 4-amino. The other is that the absolute IC50 values in these PRAs 
are consistently lower than those for enzyme inhibition for all except FeqAmDFSA (4) and 
impressively in all cases are in the low nanomolar range. The relatively poor PRA data observed 
with FeqAmDFSA (4) likely reflects the faster reactivation of NA inactivated by this compound. 
 
Efficacy against resistant strains. The DFSA derivatives proved effective in vitro against a 
series of resistant strains, with the FeqGuDFSA (5) again proving to be the most widely active 
(Table 2). All compounds proved effective against virus with the H275Y mutation that affects 
binding of the isopentyl side chain of oseltamivir, as might be predicted. This is also reflected in 
the very similar kinetic data measured for each DFSA derivative with another H275Y 
oseltamivir resistant strain and its parent (Table 1). While the E119G mutation, which affects 
interactions with the inhibitor’s guanidine (5), led to a 20-fold reduction in efficacy of 
FaxGuDFSA, this was much less severe than the 250-fold reduction in zanamivir binding. The 
effectiveness of the FeqGuDFSA is particularly noteworthy, and highlights the different 
resistance profiles and modes of action of the DFSAs and zanamivir. Clearly, selection against 
transition state analogue binding (zanamivir) does not suppress covalent intermediate formation. 
Indeed in the case of the E119 mutations that target the 4-position, FeqGuDFSA (5) actually 
performed 10-fold better against the mutant strains than against the wild type. This most likely 
reflects slower reactivation of the trapped intermediate formed on the mutant, due to disruption 
of transition state-stabilizing interactions. This excellent profile against otherwise resistant 
strains is extremely promising and supports the concept of mechanism-based inhibition as a 
means to minimize selection of resistant strains.  
 
In vivo efficacy studies.  
Prior to in vivo efficacy studies in mouse models, the pharmacokinetic properties of FaxGuDFSA 
(3) as a representative DFSA derivative were evaluated for administration by intravenous and 
intranasal routes, and compared with data collected in parallel for zanamivir. Levels of 3 in 
blood, lung and trachea were measured and half-lives determined. Intranasal dosing resulted in 
92% bioavailability compared to that seen with intravenous injection, along with approximately 
seven times higher peak concentrations (Cmax) and ten times higher total exposure (AUC(0-120 min)) 
in both lung and trachea compared to the intravenous route. Further, the plasma half-life of 
FaxGuDFSA (3) was also significantly longer after intranasal administration than after IV 
injection (table S2). The general similarity of this pharmacokinetic behavior to that of zanamivir, 
consistent with the similar polarities of the two compounds, encouraged us to test the efficacy via 
intranasal administration, using zanamivir as our control.  
 Efficacy tests were conducted using a mouse-adapted influenza A virus strain, A/Hong 
Kong/1/68 (H3N2) (26). Balb/c mice were treated with either DFSA derivative, zanamivir or 
saline twice daily by intranasal administration, starting two hours prior to infection. Body 
weights and general condition were monitored and when the animals lost 20% body weight they 
were euthanized and scored as non-survivors. In an initial study using 1 mg/kg/day of DFSA 
derivatives FaxGuDFSA showed superior results to FaxAmDFSA in prolonging the survival of 
animals. When FaxGuDFSA was tested at a higher dose of 10 mg/kg/day it protected all the 
mice from the lethal infection, as did zanamivir (Fig. 2A). In order to confirm that the 
compounds were acting as anti-viral agents, the viral RNA loads in lung tissue were measured by 
qPCR. These results confirmed that survival was indeed associated with suppression of viral 
replication, in a similar manner to the effect of zanamivir.   
Dose-dependency of FeqGuDFSA in the protection of mice was demonstrated with 100% 
efficacy at 10 mg/kg/day and less protection at lower doses (Fig. 2B and table S3). The 
compounds induced no ill-effect in the treated animals during the experiments compared to the 
saline control. 
 
Conclusions   
The DFSAs represent a novel class of potent, mechanism-based, specific NA inhibitor 
functioning by transient formation of a covalent intermediate species. Their high efficacy as 
enzyme inhibitors is matched by excellent anti-viral activity in cell-based plaque size reduction 
assays, at levels similar or superior to those for zanamivir. Furthermore, they show good 
inhibition of NAs from zanamivir or oseltamivir-resistant influenza virus strains, indicating an 
altered resistance profile. Most importantly, they function well in controlling influenza infections 
in an animal model, at levels comparable to those used for zanamivir. The similarity of their 
structure to that of the natural substrate and their mechanism-based design should decrease the 
selection of resistant viral strains, improving the therapeutically useful `lifetime` of this drug 
class. 
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Fig. 1. Structures of key influenza therapeutics, mechanism of action of DFSAs and X-ray 
structure of inhibited enzyme. A) Chemical structures of cell surface sialic acids, the 
neuraminidase transition state, zanamivir (Relenza
®
) and oseltamivir (Tamiflu
®
); B) Mechanism 
of action of the 2,3-difluorosialic acids (DFSAs); C) X-ray crystallographic structure of the 
active site of the enzyme trapped as its 3-fluoro(eq)-4-guanidino-sialyl-enzyme intermediate 
(elimination product is in pale cyan) overlaid with omit (27) electron density map shown as a 
grey mesh contoured at 1 within 1.6 Å of ligands. The electron density extends from the ligand 
molecule to Y406, suggesting a covalent link between the inhibitor’s C-2 atom and the OH of 
Y406; D). Diagram of interactions (orange dashed lines; distances in Å) with the sialic acid in 
the covalently inhibited enzyme. The corresponding diagram of interactions for the elimination 
product is shown in fig. S4. 
 
 
Fig. 2. Efficacy of FaxGuDFSA (3), FeqGuDFSA (5) and zanamivir in treating H3N2 
influenza infection in the Balb/c mouse. A) The top graph shows body weight over the 17 day 
observation period. Animals that lost 20% of initial weight were recorded as non-survivors, as 
indicated in the survival plot (inset). In a parallel set of animals, viral RNA loads were measured 
over 7 days by qPCR (bottom graph). In this group, all untreated animals survived only 3 days. 
B) Dose dependent efficacy of FeqGuDFSA (5) (1-10 mg/kg/d) and zanamivir. FeqGuDFSA (5) 
was partly (20%) effective at protecting animals at 3 mg/kg/d ((*) Mantel Cox p = 0.03), whereas 
a 10 mg/kg/d dose was 100% effective (dotted line, (***) Mantel Cox p < 0.001). 
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Table 3. IC50 values in the plaque size reduction assay. 
 
  
Table 1. Inactivation and reactivation parameters for difluorosialic acids (DFSAs). *
 
 
Compound Virus
† ki/Ki 
(min
-1
mM
-1
) 
t1/2 (inac) 
(min) 
t1/2 (reac) 
(min) 
DFSA (1) 
G70C H1N9 196 N.D.
‡
 < 1 min 
FaxAmDFSA (2) 
Brisbane H1N1 106 2.1 6900 
Brisbane H1N1 H275Y 29 2.5 3450 
California H1N1 95 1.7 6900 
G70C H1N9 74 4.0 2300 
Hong Kong H3N2  140 20.8 >6900 
FaxGuDFSA (3) 
Brisbane H1N1 371 7.4 >6900 
Brisbane H1N1 H275Y 160 9.2 >6900 
California H1N1 93 20.9 >6900 
G70C H1N9 246 6.8 >6900 
Hong Kong H3N2  470 20.2 >6900 
FeqAmDFSA (4) 
Brisbane H1N1 3479 0.9 256 
Brisbane H1N1 H275Y 849 0.2 117 
California H1N1 4422 0.4 46 
G70C H1N9 4332 0.8 49 
Hong Kong H3N2  5662 --- 153 
FeqGuDFSA (5) 
Brisbane H1N1 5812 0.3 1380 
Brisbane H1N1 H275Y 2992 0.5 460 
California H1N1 7594 0.9 690 
G70C H1N9 3879 0.5 363 
Hong Kong H3N2  5737 0.8 1380 
*Refer to table S4 for full kinetic parameters. 
†
Brisbane H1N1 = A/Brisbane/59/07; Brisbane 
H1N1 H275Y = A/Brisbane/59/07 oseltamivir-resistant; California H1N1 = A/California/07/09; 
G70C H1N9 = A/NWS/G70C/75; Hong Kong H3N2 = A/HongKong/01/68; 
‡
N.D. = Not 
Determined.  
 
Table 2. IC50 values (nM) in the enzyme inhibition assay for wild type and mutant pairs. 
 
Virus*
 
Zanamivir Oseltamivir 
DFSA 
(1) 
FaxAm 
DFSA 
(2) 
FaxGu 
DFSA 
(3) 
FeqAm 
DFSA 
(4) 
FeqGu 
DFSA 
(5) 
B/Perth 8.9 104.4 70 210 54 5.4 4.5 
B/Perth D197E 257.5 708.0 170 340 162 16 8 
A/Mississippi 
H1N1 
1.9 3.1 80 840 115 45 13 
A/Mississippi 
H1N1 H275Y 
2.2 2440 120 2210 217 86 44 
A/Fukui H3N2 3.8 1.7 1380 4710 2006 71 25 
A/Fukui H3N2 
E119V 
3.4 260.0 240 2440 998 265 2.4 
G70C H1N9 2.7 2.8 1190 2700 66.7 270 140 
G70C H1N9 
E119G 
678.4 2.9 1150 1600 1433 73 17 
Red highlights resistance to zanamivir or oseltamivir. The IC50 is the concentration of inhibitor 
which reduces enzyme activity by 50% compared to the control uninhibited value. Values are the 
means of duplicate assays. *B/Perth = B/Perth/211/01; B/Perth D197E = B/Perth/211/01 
zanamivir and oseltamivir-resistant; A/Mississippi H1N1 = A/Mississippi/3/01; A/Mississippi 
H1N1 H275Y = A/Mississippi/3/01 oseltamivir-resistant; A/Fukui H3N2 = A/Fukui/45/01; 
A/Fukui H3N2 E119V = A/Fukui/45/01oseltamivir-resistant; G70C H1N9 = A/NWS/G70C/75; 
G70C H1N9 E119G = A/NWS/G70C/75 zanamivir-resistant 
 
 
 
Table 3. IC50 values in the plaque size reduction assay. 
 
Virus*
 
Zanamivir 
DFSA 
(1) 
FaxAm 
DFSA 
(2) 
FaxGu 
DFSA 
(3) 
FeqAm 
DFSA 
(4) 
FeqGu 
DFSA (5) 
B/Perth 10 nM 1 µM 100 nM 
10-100 
nM 
10-100 
nM 
1 nM 
A/Mississippi H1N1 ≤1 nM 1 µM 100 nM 10 nM 100 nM 1 nM 
A/Fukui H3N2 100 nM 100 µM 1 µM 100 nM 1 µM 10 nM 
G70C H1N9 1-10 nM 1-10 µM 1 µM 1-10 nM 1 µM 10 nM 
The IC50 is the concentration of inhibitor required to reduce plaque size by 50%. Values are the 
means of duplicate assays. *B/Perth = B/Perth/211/01; A/Mississippi H1N1 = 
A/Mississippi/3/01; A/Fukui H3N2 = A/Fukui/45/01; G70C H1N9 = A/NWS/ G70C/75. 
 
Supplementary Materials: 
Materials and Methods 
Figures S1-S8 
Tables S1-S3 
References (27-47) 
 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
C                            D 
 
 
 
 
 
 
 
 
 
Fig. 1. Structures of key influenza therapeutics, mechanism of action of DFSAs and X-ray 
structure of inhibited enzyme. A) Chemical structures of cell surface sialic acids, the 
neuraminidase transition state, zanamivir (Relenza
®
) and oseltamivir (Tamiflu
®
); B) Mechanism 
of action of the 2,3-difluorosialic acids (DFSAs); C) X-ray crystallographic structure of the 
active site of the enzyme trapped as its 3-fluoro(eq)-4-guanidino-sialyl-enzyme intermediate 
(elimination product is in pale cyan) overlaid with omit (27) electron density map shown as a 
grey mesh contoured at 1 within 1.6 Å of ligands. The electron density extends from the ligand 
molecule to Y406, suggesting a covalent link between the inhibitor’s C-2 atom and the OH of 
Y406; D). Diagram of interactions (orange dashed lines; distances in Å) with the sialic acid in 
the covalently inhibited enzyme. The corresponding diagram of interactions for the elimination 
product is shown in fig. S4. 
 
Fig. 2. Efficacy of FaxGuDFSA (3), FeqGuDFSA (5) and zanamivir in treating H3N2 
influenza infection in the Balb/c mouse. A) The top graph shows body weight over the 17 day 
observation period. Animals that lost 20% of initial weight were recorded as non-survivors, as 
indicated in the survival plot (inset). In a parallel set of animals, viral RNA loads were measured 
over 7 days by qPCR (bottom graph). In this group, all untreated animals survived only 3 days. 
B) Dose dependent efficacy of FeqGuDFSA (5) (1-10 mg/kg/d) and zanamivir. FeqGuDFSA (5) 
was partly (20%) effective at protecting animals at 3 mg/kg/d ((*) Mantel Cox p = 0.03), whereas 
a 10 mg/kg/d dose was 100% effective (dotted line, (***) Mantel Cox p < 0.001). 
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